echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > In the first half of the year, the VAT reform and tax reduction reached 436.9 billion yuan, which made pharmaceutical enterprises feel very happy

    In the first half of the year, the VAT reform and tax reduction reached 436.9 billion yuan, which made pharmaceutical enterprises feel very happy

    • Last Update: 2019-07-24
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    [pharmaceutical Station industry trends] in the first half of this year, a total of 1179.9 billion yuan of tax and fee reductions and 1038.7 billion yuan of tax reductions were added nationwide, according to data released by the State Administration of Taxation on July 23 Among them, 436.9 billion yuan was reduced in value-added tax reform, 116.4 billion yuan in inclusive policies for small and micro enterprises, and 307.7 billion yuan in individual income tax two-step reform On April 1, the deepening VAT reform of this year's tax reduction and fee reduction was officially implemented, and enterprises will enjoy the tax policy of reducing the VAT rate from 16% to 13% Among them, as one of the beneficiaries of the policy, the tax cut dividend reduces the burden of enterprises and will help them develop more steadily and vigorously The industry said that the benefits of tax reduction and fee reduction policy to enterprises are real "On the one hand, the tax cost pressure has been reduced and the profit level of the enterprise has been improved; on the other hand, the saved funds can be used to do more publicity, enhance the innovation ability of the enterprise and expand the scale of the enterprise." Some pharmaceutical companies pointed out that the value-added tax burden from January to March 2019 was 2.31%; the value-added tax burden in April was 2.82%, with an increase of 18380.92 yuan compared with that before the reform; by may, the value-added tax burden was 2.3%, with a reduction of 33956.13 yuan compared with that before the reform The tax increase in May benefited from the original 16% tax rate for all its input, and enjoyed the preferential tax rate reduction It can be seen that the value-added tax reform really brings "big gift package" to enterprises, and injects "heart power" into enterprises Previously, yuekang pharmaceutical's financial director predicted that the group could achieve tax reduction of nearly 100 million yuan in 2019 According to the data, in 2018, the company's R & D expenses plus deduction of one tax preference will reach more than 3 million yuan Over the past three years, the project has achieved a cumulative tax reduction of more than 8 million yuan The implementation of the tax reduction and fee reduction policy will further stimulate the innovation vitality of enterprises and reduce the production cost of enterprises Yuekang Pharmaceutical Co., Ltd said it plans to reduce taxes and dividends to benefit the people, reduce drug prices, invest the cost savings in research and development, and develop more and better new drugs According to the judgment of Yikang pharmaceutical, the company is expected to achieve a revenue of 320 million yuan, a profit of 45 million yuan and a tax of 26.5 million yuan in 2019 In addition, the company is expected to save up to 8.3 million yuan in taxes in 2019 Huahong pharmaceutical said it expects to reduce its spending on value-added tax and social security by about 6 million this year, according to the tax reduction and fee reduction policy formulated by the state The value-added tax paid by CIIC pharmaceutical industry used to be 16% and 10% Since April, the 16% value-added tax rate has been reduced to 13%, and the 10% value-added tax rate has been reduced to 9% This also means that for a drug of 116 yuan, the value-added tax of 3.2 yuan which was originally borne by CIIC Pharmaceutical Co., Ltd is only 2.7 yuan, which will save a lot of tax for the enterprise In addition to local pharmaceutical enterprises, multinational pharmaceutical enterprises are also enjoying the "rain" of tax reduction and fee reduction For example, Sanofi (according to the forecast of Hangzhou, it is expected that the deepening of VAT reform will be a major good for enterprises The amount of tax reduction is expected to reach 150 million yuan, which strongly supports the better development of enterprises in China In general, the reduction of VAT rate brings "real gold and silver" to pharmaceutical enterprises In the context of the current changes in the pharmaceutical pattern and the increasingly fierce competition in the industry, it is conducive to enhancing the confidence and confidence of enterprises, as well as allowing enterprises to invest more funds in R & D Pharmaceutical enterprises should seize the spring breeze of policies, reasonably control costs, increase R & D efforts, strengthen the innovation ability of enterprises, and help enterprises to become bigger and stronger, so as to help China's pharmaceutical industry develop towards high quality.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.